Citius Pharmaceuticals, Inc. (OTCQB: CTXR) is engaged as a specialty pharmaceutical company, with the focus on cancer care and critical care products. The company’s flagship product, Mino-Lok, is used to help with the treatment of infected central venous catheters and blood stream infections. Shares of the specialty pharmaceutical company are soaring 29.23% through afternoon trading on Wednesday, January 11, 2017. Over the past three months, Citius Pharmaceuticals, Inc., has seen average daily volume of 65,909 shares. However, the stock has seen volume of 348,611 shares or dollar volume of $292,833.
Shares of Citius Pharmaceuticals, Inc. shot up today, after the company announced how its Phase 3 study treatment, Mino-Lok, will address resistant pathogens. Mino-Lok will help with the treatment of infected central venous catheters and blood stream infections. Using Mino-Lok and systemic antibiotics, they will be able to salvage infected central venous catheters and help deter severe infections from their use. Here is the press release detailing of the Mino-Lok treatment:
Citius Pharmaceuticals, Inc. Press Release:
CRANFORD, N.J., Jan. 11, 2017 /PRNewswire/ — Citius Pharmaceuticals, Inc. (“Citius”) (OTC BB: CTXR), a specialty pharmaceutical company focused on adjunctive cancer care and critical care drug products, said today that the phase 3 study of Mino-Lok™ treatment of infected central venous catheters (CVCs) will include the most common organisms that are associated with catheter related blood stream infections (CRBSIs), and that many of these pathogens have been shown to be resistant to many of the antibiotics being used today. Mino-Lok is being developed as an adjunctive therapy for the treatment of catheter-related or central line associated bloodstream infection (CRBSI/CLABSI) in combination with appropriate systemic antibiotic(s), to salvage infected central venous catheters (CVCs), to preserve central venous access, and to avoid the complications and morbidities associated with catheter removal and reinsertion.
Mr. Myron Holubiak, President and CEO stated, “There has been an alarming growth of antibiotic resistance in hospital acquired infections. The CDC has designated carbapenem-resistant Enterobacteriaceae (CRE) as being an ‘Urgent Threat’ meaning that these infections are untreatable or hard-to-treat, and are on the rise in medical facilities. CREs have become resistant to all or nearly all of the antibiotics we have today, and almost half of CRE bacteremic hospital patients will die from their infection.
Additionally, CDC considers Methicillin Resistant Staphylococcus aureus (MRSA) to be a ‘Serious Threat.’ MRSA causes a range of illnesses, from skin and wound infections to pneumonia and bloodstream infections that can cause sepsis and death. Staph bacteria, including MRSA, are one of the most common causes of healthcare-associated infections.
We were encouraged by the work performed by the MD Anderson Cancer Center that showed Mino-Lok to be highly effective in vitro against these highly virulent organisms that form biofilm to protect their colonies from antibiotic attack. We have designed our phase 3 study to assure that these virulent and resistant pathogens are included, and we expect that Mino-Lok therapy will be effective in salvaging the CVCs in these settings.”
There are currently no approved therapies to salvage infected CVCs.
Mino-Lok™ is under investigation and not approved for commercial use.
About Citius Pharmaceuticals, Inc.
Citius is a specialty pharmaceutical company dedicated to the development and commercialization of critical care products with a focus on anti-infectives, cancer care and unique prescription products using innovative, patented or proprietary formulations of previously approved active pharmaceutical ingredients. We seek to achieve leading market positions by providing therapeutic products that address unmet medical needs. By using previously approved drugs with substantial safety and efficacy data, we seek to reduce the risks associated with pharmaceutical product development and regulatory requirements. We focus on developing products that have intellectual property protection and competitive advantages to existing therapeutic approaches.